Acadia's Nuplazid rebounds in schizophrenia with study win

Investigators hope their research will lead to sensor systems that connect biology to electronic circuits.
Acadia said it would launch a second trial for Nuplazid in the first half of 2020. (Pixabay)

Acadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a phase 2 win could help Acadia get over the top. 

Nuplazid added to standard-of-care antipsychotics bested antipsychotics alone in reducing the negative symptoms of schizophrenia after 26 weeks in patients with controlled positive symptoms, according to top-line data from Acadia's phase 2 Advance study. 

Acadia said it would launch a second pivotal study for the 34-milligram dose of Nuplazid in the first half of 2020, with additional results from the Advance study set to be presented at a future medical meeting.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

“The positive efficacy results and favorable tolerability profile of (Nuplazid) observed in the Advance study represent an important step forward for patients and their families, given the lack of currently approved treatment options for the negative symptoms of schizophrenia,” Acadia President Serge Stankovic said in a release.

RELATED: Acadia's Nuplazid flops schizophrenia trial on the heels of DOJ marketing probe

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.